These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 20497922

  • 1. Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.
    Gogas H, Pectasides D, Kostopoulos I, Lianos E, Skarlos D, Papaxoinis G, Bobos M, Kalofonos HP, Petraki K, Pavlakis K, Bafaloukos D, Fountzilas G.
    Clin Breast Cancer; 2010 Jun; 10(3):230-7. PubMed ID: 20497922
    [Abstract] [Full Text] [Related]

  • 2. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY, Zhang P, Zhang BL, Wang X, Xu XZ, Zheng S, Wang JY, Cai RG, Yuan P, Ma F, Fan Y, Xu BH.
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [Abstract] [Full Text] [Related]

  • 3. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
    Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J.
    Cancer; 2010 Sep 15; 116(18):4227-37. PubMed ID: 20549829
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
    Dede DS, Gumuskaya B, Guler G, Onat D, Altundag K, Ozisik Y.
    J BUON; 2013 Sep 15; 18(1):57-63. PubMed ID: 23613389
    [Abstract] [Full Text] [Related]

  • 5. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
    Matsubara N, Mukai H, Fujii S, Wada N.
    Breast Cancer Res Treat; 2013 Jan 15; 137(1):203-12. PubMed ID: 23184081
    [Abstract] [Full Text] [Related]

  • 6. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
    Chen S, Chen CM, Yu KD, Zhou RJ, Shao ZM.
    Ann Surg Oncol; 2012 Sep 15; 19(9):3002-11. PubMed ID: 22437200
    [Abstract] [Full Text] [Related]

  • 7. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.
    Cancer Chemother Pharmacol; 2012 Feb 15; 69(2):533-46. PubMed ID: 21901395
    [Abstract] [Full Text] [Related]

  • 8. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L, Morabito F, Provinciali N, Canobbio L, Meszaros P, Naso C, Murialdo R, Boitano M, Salvi S, Ferrarini M.
    Eur J Surg Oncol; 2013 Oct 15; 39(10):1046-52. PubMed ID: 23890870
    [Abstract] [Full Text] [Related]

  • 9. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
    Torrisi R, Balduzzi A, Ghisini R, Rocca A, Bottiglieri L, Giovanardi F, Veronesi P, Luini A, Orlando L, Viale G, Goldhirsch A, Colleoni M.
    Cancer Chemother Pharmacol; 2008 Sep 15; 62(4):667-72. PubMed ID: 18064460
    [Abstract] [Full Text] [Related]

  • 10. Measuring β-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer.
    Chen X, Wu J, Lu H, Huang O, Shen K.
    Cancer Sci; 2012 Feb 15; 103(2):262-8. PubMed ID: 22035021
    [Abstract] [Full Text] [Related]

  • 11. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 12. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.
    Sikov WM, Dizon DS, Strenger R, Legare RD, Theall KP, Graves TA, Gass JS, Kennedy TA, Fenton MA.
    J Clin Oncol; 2009 Oct 01; 27(28):4693-700. PubMed ID: 19720916
    [Abstract] [Full Text] [Related]

  • 13. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
    Hsu C, Huang CS, Chao TY, Lu YS, Bu CF, Chen MM, Chang KJ, Cheng AL.
    Cancer; 2002 Nov 15; 95(10):2044-50. PubMed ID: 12412156
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
    Yardley DA, Raefsky E, Castillo R, Lahiry A, Locicero R, Thompson D, Shastry M, Burris HA, Hainsworth JD.
    Clin Breast Cancer; 2011 Oct 15; 11(5):297-305. PubMed ID: 21729666
    [Abstract] [Full Text] [Related]

  • 15. Phase II trial of preoperative chemotherapy for breast cancer: Japan Breast Cancer Research Network (JBCRN)-02 trial.
    Iwase S, Yamamoto D, Kuroda Y, Kawaguchi T, Kitamura K, Odagiri H, Teramoto S, Akazawa K, Nagumo Y.
    Anticancer Res; 2011 Apr 15; 31(4):1483-7. PubMed ID: 21508407
    [Abstract] [Full Text] [Related]

  • 16. A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers.
    Yerushalmi R, Hayes MM, Gelmon KA, Chia S, Bajdik C, Norris B, Speers C, Hassell P, O'Reilly SE, Allan S, Shenkier TN.
    Clin Breast Cancer; 2009 Aug 15; 9(3):166-72. PubMed ID: 19661040
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.